While the company reported strong growth in Ex-U.S. markets and maintained a solid cash position, challenges in the U.S. market, including a decline in revenues and increased expenses, present ongoing headwinds. The progress in radiopharmaceutical R&D and DANYELZA's inclusion in NCCN guidelines are positive steps, but the projected Q2 revenue decline tempers the overall outlook.

Company Guidance

During the Y-mAbs Therapeutics First Quarter 2025 Earnings Conference Call, the company provided a detailed financial and strategic update. For the first quarter of 2025, Y-mAbs reported DANYELZA net product revenues of $20.9 million, marking an 8% increase from the previous year. Ex-U.S. revenues saw a significant rise, totaling $7.5 million, driven primarily by the named patient program in Western Asia. However, U.S. revenues declined by 28% to $13.4 million due to competitive pressures and ordering patterns. The company maintained a strong cash position with $60.3 million, projecting a runway into 2027. Y-mAbs has reiterated its full-year revenue guidance and announced a second-quarter revenue forecast between $17 million and $19 million. The company also highlighted its ongoing Radiopharmaceutical initiatives, including advancements in their GD2-SADA and CD38-SADA Phase I trials.

DANYELZA Revenue Growth

DANYELZA net product revenues reached $20.9 million in Q1 2025, representing an 8% increase from the first quarter of the previous year.

Ex-U.S. Market Expansion

Ex-U.S. DANYELZA net product revenues were $7.5 million, marking an 816% increase from the prior year period, driven by growth in Western Asia, Eastern Asia, and Latin America.

Cash Position and Runway

The company maintains a strong cash position with $60.3 million in cash, providing an anticipated runway into 2027 based on current operations.

Radiopharmaceutical R&D Progress

Completion of Part A of the GD2-SADA Phase I clinical trial and dosing of the first patient in the CD38-SADA Phase I clinical trial in relapsed/refractory non-Hodgkin Lymphoma.

Inclusion in NCCN Guidelines

DANYELZA, in combination with chemotherapy, was added to the NCCN guidelines for the treatment of relapsed/refractory neuroblastoma.

Y-Mabs Therapeutics (YMAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

YMAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.22 / -	-0.16	―	―	―
Aug 08, 2025	2025 (Q2)	-0.26 / -0.07	-0.21	66.67% (+0.14)	―	―
May 13, 2025	2025 (Q1)	-0.21 / -0.12	-0.15	20.00% (+0.03)	―
Mar 04, 2025	2024 (Q4)	-0.12 / -0.15	-0.02	-650.00% (-0.13)	―
Nov 08, 2024	2024 (Q3)	-0.16 / -0.16	-0.18	11.11% (+0.02)	―
Aug 12, 2024	2024 (Q2)	-0.12 / -0.21	-0.14	-50.00% (-0.07)	―
May 07, 2024	2024 (Q1)	-0.14 / -0.15	-0.15	0.00% (0.00)	―
Feb 29, 2024	2023 (Q4)	-0.20 / -0.02	0.03	-166.67% (-0.05)	―
Nov 13, 2023	2023 (Q3)	-0.19 / -0.18	-0.63	71.43% (+0.45)	―
Aug 10, 2023	2023 (Q2)	-0.24 / -0.14	-0.94	85.11% (+0.80)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

YMAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 08, 2025	$8.52	$8.51	-0.12%
May 13, 2025	$4.07	$4.16	+2.21%
Mar 04, 2025	$5.19	$4.96	-4.43%
Nov 08, 2024	$15.55	$15.48	-0.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Y-Mabs Therapeutics (YMAB) report earnings?

Y-Mabs Therapeutics (YMAB) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Y-Mabs Therapeutics (YMAB) earnings time?

Y-Mabs Therapeutics (YMAB) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is YMAB EPS forecast?

YMAB EPS forecast for the fiscal quarter 2025 (Q3) is -0.22.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing